导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 16.22% | 540/4773 |
| 近一周 | -1.67% | 2498/5465 |
| 近一月 | -1.80% | 1306/5421 |
| 近一季 | -4.81% | 1901/5231 |
| 近半年 | 4.21% | 891/4920 |
| 近一年 | 22.33% | 410/4394 |
| 近两年 | 96.58% | 662/2954 |
| 近三年 | 62.21% | 449/2253 |
| 成立以来 | 46.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.59% 498/4961 |
22.39% 1130/5312 |
- - |
- - |
| 2025 | 33.27% 1126/4813 |
1.98% 1502/3635 |
5.48% 583/4076 |
20.74% 1927/4524 |
2.61% 899/4813 |
| 2024 | 8.56% 1538/3463 |
-0.84% 1146/2808 |
-4.55% 1522/3014 |
13.35% 2184/3129 |
1.18% 1109/3463 |
| 2023 | -4.15% 668/2656 |
6.85% 637/2280 |
-4.69% 1255/2385 |
-2.70% 723/2515 |
-3.28% 645/2655 |
| 2022 | -19.28% 829/2207 |
-12.45% 613/1919 |
4.06% 1064/2016 |
-10.41% 399/2113 |
-1.11% 1679/2208 |
| 2021 | 15.90% 291/1822 |
-1.24% 454/1255 |
12.75% 311/1330 |
4.45% 349/1466 |
-0.35% 1225/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证500指数增强C VS. 长安沪深300非周期A(740101) |